Dr. Galsky on Progression on Immunotherapy in Bladder Cancer

Matthew Galsky, MD,
Published: Friday, Jan 05, 2018



Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses the next steps following progression on immunotherapy for patients with bladder cancer.

There is a growing understanding of the resistance to checkpoint inhibitors, explains Galsky. One of the main reasons that patients do not respond to checkpoint inhibitors is because their tumors are not immunogenic and have not developed a preexisting immune response, which is necessary.
 


Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses the next steps following progression on immunotherapy for patients with bladder cancer.

There is a growing understanding of the resistance to checkpoint inhibitors, explains Galsky. One of the main reasons that patients do not respond to checkpoint inhibitors is because their tumors are not immunogenic and have not developed a preexisting immune response, which is necessary.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x